For background on the Fabrazyme case, see: https://www.keionline.org/fabrazyme
The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.
Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)
On December 19, 2007, the The Energy Independence and Security Act of 2007 was enacted as Public Law 110-140. The Act created two new innovation inducement prizes to stimulate innovation in the field of energy:
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading
Written submission U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures, On the topic of Direct funding, subsidies and incentives for the development… Continue Reading
Sep 2, 2009 The Bayh-Dole Act (or University and Small Business Patent Procedures Act) was originally enacted in 1980 as Public Law 96-517, and was amended in 1984 by Public Law 98-620. Among other things, the Bayh-Dole Act was designed… Continue Reading
For more information, KEI general page on the Bayh Dole Act, or one of the mini Bayh-Dole timelines, such as the ones on transparency, march-in rights or royalty free uses. TIMELINE 1980 1980. October 21. Public Law 96-480. Stevenson-Wydler Technology… Continue Reading
We have received a copy of an amendment to the September 2006 voluntary License Agreement between Gilead Sciences, Inc and Ranbaxy Laboratories, Ltd concerning the manufacture and sale of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine for the treatment of HIV-AIDS.
Ralph Nader P.O. Box 19312 Washington, DC 20036 July 23, 2001 Dr. Gro Harlem Brundtland Director-General World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland Dear Dr. Brundtland: It has been encouraging in recent years to see the WHO… Continue Reading
July 6, 2001 Mr. Ralph Nader P.O. Box 19312 Washington, D.C. 20036 Dear Mr. Nader: I am writing in response to the letter from you and your colleagues requesting that the Department of Health and Human Services (HHS) grant the… Continue Reading
Ralph Nader P.O. Box 19312 Washington, DC 20036 James Love Consumer Project on Technology P.O. Box 19367 Washington, DC 20036 Robert Weissman Essential Action P.O. Box 19405 Washington, DC 20036 March 28, 2001 Secretary Tommy Thompson Department of Health and… Continue Reading